TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30562056

Group type: EXPERIMENTAL
Intervention: ACTIVE training (aerobic exercise intervention)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Nontraining group (control)
Number of subjects: 40
Study: 27544904

Group type: EXPERIMENTAL
Intervention: Reboxetine 4 mg monotherapy
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Reboxetine 4 mg combined with desmopressin
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 25377946

Group type: EXPERIMENTAL
Intervention: Pamidronate disodium (PAM) short-term treatment (PAM-S) for 2 weeks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pamidronate disodium (PAM) long-term treatment (PAM-L) for 10 weeks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pamidronate disodium (PAM) treatment
Number of subjects: 60

Group type: COMPARATOR
Intervention: ACLT group (control)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: PAM group
Number of subjects: 60
Study: 23525511

Group type: EXPERIMENTAL
Intervention: Mometasone furoate/formoterol fumarate metered-dose inhaler (MF/F MDI)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Mometasone furoate/formoterol fumarate metered-dose inhaler (MF/F MDI) with a spacer
Number of subjects: 14

Group type: COMPARATOR
Intervention: Mometasone furoate dry-powder inhaler (MF DPI)
Number of subjects: 14
Study: 20799005

Group type: EXPERIMENTAL
Intervention: Established guidelines for blood pressure control (EST)
Number of subjects: 762

Group type: EXPERIMENTAL
Intervention: Established guidelines plus the Dietary Approaches to Stop Hypertension (DASH) dietary pattern (EST + DASH)
Number of subjects: 762

Group type: COMPARATOR
Intervention: Advice only (ADVICE)
Number of subjects: 762

Group type: EXPERIMENTAL
Intervention: Change in dietary intake and weight loss
Number of subjects: 762

Group type: EXPERIMENTAL
Intervention: Change in physical activity
Number of subjects: 762

Group type: EXPERIMENTAL
Intervention: Change in sodium and low-fat dairy intake
Number of subjects: 762
Study: 27408116

Group type: EXPERIMENTAL
Intervention: Levonorgestrel Releasing Intrauterine System (LNG‐IUS)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Copper T device (Cu T)
Number of subjects: 70
Study: 15705477

Group type: EXPERIMENTAL
Intervention: 10 microg CRM197-Hib conjugate
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: 5 microg CRM197-Hib conjugate
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: 2.5 microg CRM197-Hib conjugate
Number of subjects: 261

Group type: EXPERIMENTAL
Intervention: 1.25 microg CRM197-Hib conjugate
Number of subjects: 261
Study: 12602669

Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg
Number of subjects: 1214

Group type: COMPARATOR
Intervention: Loratadine 10 mg
Number of subjects: 1214

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1214
Study: 10526997

Group type: EXPERIMENTAL
Intervention: IQOLA version of SF36 health survey
Number of subjects: 946

Group type: COMPARATOR
Intervention: Geneva version of SF36 health survey
Number of subjects: 946
Study: 8784214

Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Valproate (VPA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Phenytoin (PHT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phenobarbital (PB)
Number of subjects: 0
Study: 1971636

Group type: EXPERIMENTAL
Intervention: Imipenem
Number of subjects: 268

Group type: COMPARATOR
Intervention: Metronidazole
Number of subjects: 268

Group type: COMPARATOR
Intervention: Triple therapy (ampicillin, gentamicin, metronidazole)
Number of subjects: 268
Study: 6993259

Group type: EXPERIMENTAL
Intervention: Anti-lymphocytic globulin (ALG) 1 g daily for 5 days
Number of subjects: 10

Group type: COMPARATOR
Intervention: Standard treatment with corticosteroids
Number of subjects: 10
Study: 31505220

Group type: EXPERIMENTAL
Intervention: Calorie information displayed on menus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calorie information displayed just to the right of the price
Number of subjects: 0

Group type: COMPARATOR
Intervention: Calorie information presence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eye-tracking data
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calorie posting
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enjoyment of the meal
Number of subjects: 0
Study: 31159780

Group type: EXPERIMENTAL
Intervention: Health-promoting lifestyle counselling (3 sessions of 45 minutes each)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Routine care provided by health centers (Control)
Number of subjects: 102
Study: 28237866

Group type: EXPERIMENTAL
Intervention: Capecitabine and bevacizumab (CAP-B) maintenance therapy
Number of subjects: 558

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 558

Group type: EXPERIMENTAL
Intervention: Capecitabine and bevacizumab (CAP-B) maintenance therapy in patients with complete or partial response
Number of subjects: 558
Study: 25468946

Group type: EXPERIMENTAL
Intervention: Metabolite matching 2-hydroxybiphenyl
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: Metabolites matching PC (22:6/20:4), (3S)-7-hydroxy-2',3',4',5',8-pentamethoxyisoflavan, or tetrapeptides
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: Multimarker score comprising all seven metabolites
Number of subjects: 431
Study: 24968526

Group type: EXPERIMENTAL
Intervention: pegylated interferon‐‐alpha2B
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 80
Study: 21425519

Group type: EXPERIMENTAL
Intervention: Preventive intervention (watchful waiting, minimally supported CBT-based self-help intervention, problem-solving treatment, referral to a primary care physician for medication if required)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 170
Study: 19263200

Group type: EXPERIMENTAL
Intervention: Impedance cardiography (IC) for cardiac output (CO) measurements
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Biventricular pacing with optimized VV intervals
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Optimal VV interval programmed according to IC measurements
Number of subjects: 24

Group type: COMPARATOR
Intervention: Comparison of optimal VV intervals identified by IC and LV dP/dt(max)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Broader VV time intervals comparison
Number of subjects: 24
Study: 17289236

Group type: EXPERIMENTAL
Intervention: Depot antipsychotics (DA)
Number of subjects: 505

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 505

Group type: EXPERIMENTAL
Intervention: Age, number of hospitalizations, site, and use of DA
Number of subjects: 505

Group type: EXPERIMENTAL
Intervention: Antipsychotic polypharmacy (APP), depot antipsychotics (DA), and clozapine
Number of subjects: 505
Study: 15285600

Group type: EXPERIMENTAL
Intervention: Credibility of promises
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Credibility of threats
Number of subjects: 0
Study: 11680799

Group type: COMPARATOR
Intervention: Healthy females (control group)
Number of subjects: 482

Group type: EXPERIMENTAL
Intervention: Females with early menopause
Number of subjects: 482
Study: 9770089

Group type: EXPERIMENTAL
Intervention: Target Controlled Infusion (Disoprifusor-TCI)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Manually Controlled Infusion
Number of subjects: 21
Study: 7861598

Group type: EXPERIMENTAL
Intervention: 5 cmH2O PSV
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 5 cmH2O PSV + 5 cmH2O PEEP
Number of subjects: 9

Group type: COMPARATOR
Intervention: Standard anesthesia circle system (control)
Number of subjects: 9
Study: 2582842

Group type: EXPERIMENTAL
Intervention: Breathing air
Number of subjects: 6

Group type: COMPARATOR
Intervention: Oxygen
Number of subjects: 6
Study: 1012896

Group type: EXPERIMENTAL
Intervention: Winning 80% of contests
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Winning 50% of contests
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Winning 20% of contests
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Competitive trait anxiety (high vs low)
Number of subjects: 0
Study: 31685272

Group type: EXPERIMENTAL
Intervention: Anaortic OPCAB (ANA) with total arterial revascularization
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: OPCAB with vein grafts using carbon dioxide surgical field flooding (CO2FF)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Conventional OPCAB with vein grafts (Control)
Number of subjects: 192
Study: 31498183

Group type: EXPERIMENTAL
Intervention: ST‐PD
Number of subjects: 153

Group type: COMPARATOR
Intervention: AFA‐PD
Number of subjects: 153
Study: 28693998

Group type: EXPERIMENTAL
Intervention: Alirocumab 75 or 150 mg, given every 2 weeks
Number of subjects: 4212

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 4212

Group type: EXPERIMENTAL
Intervention: Alirocumab 75 or 150 mg
Number of subjects: 4212

Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 4212
Study: 26048739

Group type: EXPERIMENTAL
Intervention: Mobile platforms
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stationary computer
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Small sized devices
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stationary and tablet platforms
Number of subjects: 0
Study: 23811187

Group type: EXPERIMENTAL
Intervention: Calorie restriction
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control (lean females)
Number of subjects: 54
Study: 21058940

Group type: EXPERIMENTAL
Intervention: Propofol-only sedation (group P)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Propofol-alfentanil combination sedation (group PA)
Number of subjects: 64
Study: 18676412

Group type: EXPERIMENTAL
Intervention: SIMV with full PSV (PS(max))
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: SIMV with partial PSV (PS(min))
Number of subjects: 10

Group type: COMPARATOR
Intervention: SIMV alone
Number of subjects: 10
Study: 17701962

Group type: EXPERIMENTAL
Intervention: Subfascial endoscopic perforator surgery (SEPS)
Number of subjects: 72

Group type: COMPARATOR
Intervention: No SEPS (standard surgery: saphenofemoral ligation, stripping and phlebectomies)
Number of subjects: 72
Study: 15119171

Group type: EXPERIMENTAL
Intervention: Needling at bilateral Neiguan (PC 6) plus oral administration of mexiletine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oral administration of mexiletine
Number of subjects: 60
Study: 11702162

Group type: EXPERIMENTAL
Intervention: Iobitridol (300 mg/ml), 120 ml
Number of subjects: 146

Group type: COMPARATOR
Intervention: Iohexol (300 mg/ml), 120 ml
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Iobitridol and Iohexol
Number of subjects: 146
Study: 9520247

Group type: EXPERIMENTAL
Intervention: Physical stimulation first group (exposed to pain induction by ice water and pressure prior to sham stimulation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham stimulation first group (received sham stimulation followed by cold water and pressure pain induction)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Physical stimulation first group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham stimulation first group
Number of subjects: 0
Study: 8035030

Group type: EXPERIMENTAL
Intervention: PFP‐2 (50 micrograms)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: PFP‐2
Number of subjects: 6
Study: 2500141

Group type: EXPERIMENTAL
Intervention: mitomycin C 15 mg/m2 plus DSM 360 mg administered into the hepatic artery (group I)
Number of subjects: 63

Group type: COMPARATOR
Intervention: mitomycin C 15 mg/m2 (group II)
Number of subjects: 63
Study: 29886318

Group type: EXPERIMENTAL
Intervention: Push back maneuver
Number of subjects: 945

Group type: COMPARATOR
Intervention: Standard vaginal delivery
Number of subjects: 945
Study: 28224449

Group type: EXPERIMENTAL
Intervention: Regadenoson 0.4 mg during recovery (Ex-Reg)
Number of subjects: 1147

Group type: COMPARATOR
Intervention: Regadenoson 0.4 mg 1 hour after inadequate exercise (Regadenoson)
Number of subjects: 1147
Study: 26195123

Group type: EXPERIMENTAL
Intervention: Rectal indomethacin (100 mg)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Placebo (2.6 g glycerin suppository)
Number of subjects: 166
Study: 24299497

Group type: EXPERIMENTAL
Intervention: Rivastigmine capsules for 8 months
Number of subjects: 130

Group type: COMPARATOR
Intervention: Identical placebo capsules for 8 months
Number of subjects: 130
Study: 21441258

Group type: EXPERIMENTAL
Intervention: MMPI‐2 validity scales
Number of subjects: 103
Study: 18488442

Group type: EXPERIMENTAL
Intervention: Humor intervention performed by Pello the clown triggering regular laughter
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Humor intervention
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (healthy controls, n = 10)
Number of subjects: 19
Study: 16545638

Group type: EXPERIMENTAL
Intervention: 15 mg folic acid daily
Number of subjects: 315

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 315
Study: 12943949

Group type: EXPERIMENTAL
Intervention: Clomipramine (150 mg/day) plus Lithium Carbonate (750 mg/day)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Clomipramine (150 mg/day) plus Placebo
Number of subjects: 141
Study: 10683055

Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (100 mg/wk intramuscularly), no exercise
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo, no exercise
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Placebo and exercise
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Testosterone and exercise
Number of subjects: 61
Study: 9596916

Group type: EXPERIMENTAL
Intervention: Hand-insertion group
Number of subjects: 910

Group type: COMPARATOR
Intervention: Ring forceps-insertion group
Number of subjects: 910
Study: 8151563

Group type: EXPERIMENTAL
Intervention: Aminobenzoate potassium (KPAB) 12 g/day
Number of subjects: 146

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study: 3277606

Group type: EXPERIMENTAL
Intervention: Oral zinc administration
Number of subjects: 151

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study: 29900614

Group type: EXPERIMENTAL
Intervention: Positive Training Group (PTG)
Number of subjects: 31

Group type: COMPARATOR
Intervention: No Training Group (NTG)
Number of subjects: 31
Study: 28782571

Group type: EXPERIMENTAL
Intervention: Third-person perspective visualisation
Number of subjects: 0

Group type: COMPARATOR
Intervention: First-person perspective visualisation
Number of subjects: 0
Study: 26270340

Group type: EXPERIMENTAL
Intervention: Tacrolimus (TAC) at 0.1 mg/kg/day, target 5‐8 ng/ml
Number of subjects: 141

Group type: COMPARATOR
Intervention: Ciclosporin A (CSA) with target 70‐150 ng/ml
Number of subjects: 141
Study: 23571174

Group type: EXPERIMENTAL
Intervention: HPV16/18 bivalent vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no new infection with HPV31/45/58)
Number of subjects: 0
Study: 21415807

Group type: EXPERIMENTAL
Intervention: Functional Restoration Program (FRP)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Active Individual Therapy (Control)
Number of subjects: 132
Study: 18457236

Group type: EXPERIMENTAL
Intervention: EsCIT + CBTI
Number of subjects: 30

Group type: COMPARATOR
Intervention: EsCIT + CTRL
Number of subjects: 30
Study: 16566934

Group type: EXPERIMENTAL
Intervention: Baseline serum müllerian-inhibiting substance (MIS) levels in patients with OHSS
Number of subjects: 30

Group type: COMPARATOR
Intervention: Baseline serum müllerian-inhibiting substance (MIS) levels in normal controls
Number of subjects: 30
Study: 12715267

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/d
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Fluoxetine 60 mg/d
Number of subjects: 320

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 320
Study: 10714093

Group type: EXPERIMENTAL
Intervention: Endomyocardial biopsy specimens from patients with DCMP
Number of subjects: 6

Group type: COMPARATOR
Intervention: Negative controls from myocardial specimens of two persons who died in motor vehicle accidents
Number of subjects: 6
Study: 9180319

Group type: EXPERIMENTAL
Intervention: Tension-band osteosynthesis
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 40
Study: 1489187

Group type: EXPERIMENTAL
Intervention: 100 mg clarithromycin
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 200 mg clarithromycin
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 400 mg clarithromycin
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 600 mg clarithromycin
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 800 mg clarithromycin
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 1200 mg clarithromycin
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 3735223

Group type: EXPERIMENTAL
Intervention: Cefaclor 125 mg tds for three days
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Cefaclor 125 mg tds for seven days
Number of subjects: 96
Study: 29292092

Group type: EXPERIMENTAL
Intervention: KB001-A
Number of subjects: 182

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study: 27814258

Group type: EXPERIMENTAL
Intervention: Nd:YAG laser treatment (1 W, 10 Hz for 60 seconds, unfocused at 0.5 cm distance)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: GaAlAs laser treatment (40 mW; 4 J/cm²; 15 seconds per point on 4 points)
Number of subjects: 23

Group type: COMPARATOR
Intervention: 2% neutral fluoride gel application (60 seconds)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Sham treatments
Number of subjects: 23
Study: 24452706

Group type: EXPERIMENTAL
Intervention: Robot-assisted arm group therapy (RAGT) + individual arm therapy (IAT) for 30 minutes each, per workday for four weeks.
Number of subjects: 50

Group type: COMPARATOR
Intervention: Individual arm therapy (IAT) for 2x30 minutes, per workday for four weeks.
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Cost of treatment with RAGT.
Number of subjects: 50
Study: 23709633

Group type: EXPERIMENTAL
Intervention: Active HF-rTMS stimulation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sham HF-rTMS stimulation
Number of subjects: 50
Study: 19945508

Group type: EXPERIMENTAL
Intervention: Group 24 (24 trials of stimulation)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Group 36 (36 trials of stimulation)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (without stimulation)
Number of subjects: 24
Study: 18425236

Group type: COMPARATOR
Intervention: High-fiber diet (approximately 30 g)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: High-fiber diet plus 10 g of hydrolyzed partially guar-gum
Number of subjects: 64
Study: 16171472

Group type: EXPERIMENTAL
Intervention: Non-catheterisation group
Number of subjects: 262

Group type: COMPARATOR
Intervention: Catheterisation group
Number of subjects: 262
Study: 13678871

Group type: EXPERIMENTAL
Intervention: Candesartan (32 mg once daily)
Number of subjects: 3023

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3023

Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 3023
Study: 10582548

Group type: EXPERIMENTAL
Intervention: Low-fat diet with one daily fish meal (3.6 g omega3 fatty acids per day)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Moderate exercise training (55% to 65% maximal oxygen consumption [VO2max])
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Light exercise training (heart rate <100 bpm)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Low-fat diet alone
Number of subjects: 55
Study: 8947318

Group type: EXPERIMENTAL
Intervention: Ultraviolet light detection of urinary riboflavin tracer
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo group in clinical trials of medications for alcoholism treatment
Number of subjects: 38
Study: 1880222

Group type: EXPERIMENTAL
Intervention: Volmax (4 mg) administered after a meal
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Proventil Repetabs (4 mg) administered after a meal
Number of subjects: 24

Group type: COMPARATOR
Intervention: Volmax (4 mg) administered in fasting state
Number of subjects: 24

Group type: COMPARATOR
Intervention: Proventil Repetabs (4 mg) administered in fasting state
Number of subjects: 24
Study: 6852412

Group type: EXPERIMENTAL
Intervention: Cimetidine (200 mg orally and intravenously)
Number of subjects: 22
Study: 31763269

Group type: EXPERIMENTAL
Intervention: Over-the-counter normal saline
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nasal decongestant drops
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nasal drops (only)
Number of subjects: 0
Study: 28027123

Group type: EXPERIMENTAL
Intervention: 80% FiO2
Number of subjects: 177

Group type: COMPARATOR
Intervention: 30% FiO2
Number of subjects: 177
Study: 25644148

Group type: EXPERIMENTAL
Intervention: Aprepitant in combination with conventional 5HT3 blocker-based prophylaxis
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control arm (conventional 5HT3 blocker-based prophylaxis only)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Aprepitant
Number of subjects: 41
Study: 24325574

Group type: EXPERIMENTAL
Intervention: Self-control failure
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Self-awareness
Number of subjects: 214

Group type: COMPARATOR
Intervention: Glucose
Number of subjects: 214
Study: 21956278

Group type: EXPERIMENTAL
Intervention: Basic treatment
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy + Basic treatment
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control group (Healthy gingiva)
Number of subjects: 130
Study: 19902479

Group type: EXPERIMENTAL
Intervention: Robot-assisted surgery using three arms
Number of subjects: 109

Group type: COMPARATOR
Intervention: Laparoscopy
Number of subjects: 109

Group type: COMPARATOR
Intervention: Laparotomy
Number of subjects: 109
Study: 17969890

Group type: EXPERIMENTAL
Intervention: Pabing Recipe 1 (PR1) plus Madopa tablets
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Pabing Recipe 3 (PR3) plus Madopa tablets
Number of subjects: 101

Group type: COMPARATOR
Intervention: Fixed Chinese recipe plus Madopa tablets
Number of subjects: 101